Lowest Price Guaranteed From USD 4,799
Companies Covered
432
Pages
690
View Count
41624
The global wearable injectors market is estimated to be worth US$ 4.3 billion in 2023 and is projected to grow up to US$ 12.10 billion in 2035 at compounded annual growth rate (CAGR) of 9% during the forecast period. With the increasing population, the incidence rates of various chronic diseases, such as diabetes, autoimmune diseases, cardiovascular diseases, and oncological diseases, are witnessing an upward trend. The pharmaceutical stakeholders have made numerous efforts by incorporating innovative strategies and patient-centered approaches to address the growing burden of chronic diseases. The current treatment options include administration of prescribed medications through oral and parenteral routes. Of these options, parenteral administration of drugs is the most prevalent method. However, it lacks patient convenience due to the requirement of frequent dosing and has other limitations, including dosing errors, risk of microbial contamination, and needlestick injuries. These factors significantly impact medication adherence and consequently affect therapeutic outcomes. In recent years, the pharmaceutical industry has witnessed many technological advancements with the emergence of the novel drug delivery devices, such as wearable injectors, autoinjectors, and pen injectors. Within wearable injectors, the on-body injectors offer sustained therapeutic effects, thereby enhancing patient adherence and treatment effectiveness. In addition, large volume wearable injectors have proven to improve medication adherence by simplifying the administration process. The advanced wearable injection device provides a wide range of dosing options, such as basal, bolus, or continuous delivery. Moreover, such devices have in-built safety mechanisms, which minimize the risk of needlestick injuries. As a result, wearable injectors have become the preferred choice for subcutaneous administration of drugs in home-care settings. The popularity of wearable injectors has prompted pharmaceutical companies and medical device developers to integrate advanced features, such as artificial intelligence algorithms, mobile applications with smart health monitoring, reminders, visual and audible drug delivery confirmation notifications into their product portfolios. With continuous innovation in this field, it is expected that the adoption of such wearable injectors will increase significantly, driving market growth in the foreseen future.
![]() |
![]() |
![]() |
The Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injectors and Wearable Infusion Pump), Usability (Disposable and Reusable), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Metabolic Disorders, Neurological Disorders, Oncological Disorders and Other Disorders) and Key Geographical Regions (North America, Europe, Asia, Latin America and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the companies providing wearable injectors during the forecast period. Key inclusions of the market report are briefly discussed below.
The growing demand for wearable injectors which allow for safe self-administration of drug volumes greater than 1 mL is driven by their significant advantages. These devices offer a high level of convenience to the patients by eliminating the risk of frequent hospital visits and needle stick injuries. The wearable infusion pumps, commonly used for the administration of insulin, provide better control to the diabetic patients by preventing multiple pricks in a day. Further, on body injector, also known as patch pump, offers an effective solution to patients requiring large-volume medications or frequent dosing by simplifying the administration process and offering reminders and tracking features. The versatility of these wearable injectors makes them suitable for a wide range of medical conditions, such as diabetes, autoimmune diseases and cardiovascular disease. In addition, the wearable injectors can deliver drugs intended for other indications, such as cancer. It is worth mentioning that, in 2017, Insulet Corporation launched the first on body injector, named Onpro wearable injector. This device was employed by Amgen as a life cycle management strategy for its blockbuster drug Neulasta when its patent expired in 2015. It launched its Neulasta on-body injector, which is being sold under the name Neulasta® Onpro®. This on body injector enabled chemotherapy patients to administer a dose of pegfilgrastim post chemotherapy without requiring them to visit hospitals. The wearable injector devices cater to the specific needs of various end users. The significant benefits offered by wearable injectors, coupled with their rising demand in the pharmaceutical industry and healthcare sector, worldwide is likely to drive market growth during the forecast period.
The current landscape of wearable injectors (large volume) features close to 90 devices capable of delivering insulin and non-insulin drugs. It is worth mentioning that 51% of the wearable injection devices are designed for the delivery of insulin, followed by devices (29%) and combinations (20%) used to deliver non-insulin drugs. The wearable injectors market is well-fragmented, featuring the presence of established players and start-ups that possess the required expertise to manufacture wearable injectors. Majority (over 50%) of the companies are based in North America, followed by emerging players headquartered across Europe (30%).
Several stakeholders have been collaborating with industry / non-industry players engaged in wearable injectors market, primarily for product / technology integration purposes. Drug developers are evaluating novel drug delivery devices for their drug candidates at preclinical stages by partnering with delivery device manufacturers. In May 2023, Viridian Therapeutics partnered with Enable Injections to evaluate its enFuse wearable injector technology for preclinical stage drug candidates. In order to cater to the growing market demand for on body injector, the device developers are also collaborating with contract manufacturing organizations to bring their devices into the market. In March 2023, Stevanato Group entered into one such collaboration with Thermo Fisher Scientific, as a part of which Stevanato provided the pre-sterilized EZ-fill cartridges and assembly equipment, while Thermo Fisher Scientific offered fill finish and final assembly services.
Owing to several advantages of on body injector, the stakeholders are also acquiring other industry players specializing in various aspects of these novel and convenient drug delivery systems. For instance, in February 2023, Insulet Corporation acquired all the patents related to a pump based insulin delivery system from Bigfoot Biomedical, in order to expand its capabilities in the wearable injectors market. In addition to this, Tandem Diabetes Care had announced the acquisition of AMF Medical in December 2022. The latter company was working on the development of an insulin patch pump / on body injector, named Sigi Patch Pump.
![]() |
![]() |
![]() |
Wearable infusion pumps are compact, lightweight devices that can be worn by patients on the belt with an attached cannula on the skin. These drug delivery devices are also known as off body injectors. These are ideal for patients who require continuous or intermittent infusions over an extended period, allowing them to move freely during the treatment. Most insulin pumps are wearable on the belt, with a tube connecting the pump to the infusion set resting in the subcutaneous fatty tissue. Various players, such as Medtronic, Tandem Diabetes Care and Roche provide wearable infusion pump for insulin delivery. According to the International Diabetes Federation, over 780 million people are expected to be living with diabetes, by 2045. Of these, a number of patients dependent on insulin are likely to move towards the use of wearable injectors, owing to their benefits associated with the improvement in quality of life. Such factors will contribute to the market growth of the wearable injectors during the forecast period.
Neulasta Onpro wearable injector was the first drug device combination to receive approval in 2015; since then, various drug-device combinations have received approvals. In 2016, Amgen launched the first on body injector delivering an antibody drug. The company’s Pushtronex system uses West Pharmaceuticals SmartDose to deliver Repatha (evolocumab), approved for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). The Repatha wearable injector provides an option of monthly single-dose delivery to the patients. In addition, D-mine infusion pump, offered by EVER Pharma was marketed in 2019. This drug device combination has automatic dosing function due to the micro rotation pump technology. In 2022, AbbVie launched Skyrizi on body injector which is used for the treatment of Crohn’s disease. Such drug device combination approvals for non-insulin drugs are driving the wearable injectors market growth. With several pharmaceutical companies collaborating with wearable injector developers to test their devices in clinical trials, more such drug device approvals are expected during the forecast period. Furthermore, the funding received by wearable injector developers have allowed them to incorporate technological advancements into the existing designs and test their devices in clinical trials. In February 2022, Enable Injections raised USD 215 million in a Series C venture funding round. Such developments will continue to drive the wearable injectors market growth during the forecast period.
The global wearable injectors market size is estimated to be worth USD 4.3 billion in 2023. With the growing demand for effective therapeutics for the treatment of various chronic diseases, the market is anticipated to grow at a CAGR of 9% during the forecast period. Presently, close to 50% of the market is captured by companies based in North America. Driven by the rising interest in wearable injectors and adoption of such devices in the US, the wearable injectors market in North America is anticipated to grow at a CAGR of 11%, during the forecast period 2023-2035. Further, the availability of reimbursement is likely to be an important factor governing the market growth of wearable injectors, owing to the higher price points of such devices.
Examples of key players (which have also been profiled in this report) manufacturing wearable injectors for the delivery of insulin and non-insulin drugs include (in alphabetical order) CCBio, CeQur, Debiotech, Enable Injections, Gerresheimer, Insulet Corporation and West Pharmaceuticals. In addition to this, prominent drug device combinations include (which have also been profiled in this report) 3M™ Hollow Microstructured Transdermal System, D-mine® Pump, Repatha wearable injector and Neulasta® (pegfilgrastim) OnPro™ Kit. This market report includes an easily searchable excel database of all the wearable injector manufacturers, worldwide.
Several recent developments have taken place in the field of wearable injectors for the delivery of insulin and non-insulin drugs. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
![]() |
![]() |
![]() |
The study features an in-depth analysis of various firms / organizations that are engaged in wearable injectors market, across different segments as defined in the below table:
Key Report Attributes | Details | |
Historical Trend |
2017-2021 |
|
Bese Year |
2022 |
|
Forecast Period |
2023-2035 |
|
Market Size 2023 |
$4.3 billion |
|
CAGR |
9% |
|
Type of Device |
|
|
Usability |
|
|
Therapeutic Area |
|
|
Key Geographical Regions |
|
|
Key Companies Profiled |
(Full list of more than 40 companies captured in the market landscape analysis is available in the report) |
|
PowerPoint Presentation (Complimentary) |
Available |
|
Customization Scope |
15% Free Customization Option |
|
Excel Data Packs (Complimentary) |
|
The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the report includes:
One of the key objectives of the market report was to estimate the existing market size and potential future growth of wearable injectors market over the coming years. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the wearable injectors for delivery of non-insulin drugs market over the forecast period 2023-2035. The report also features the likely distribution of the current and the forecasted opportunity across various segments, such as type of device (patch pump / injector and infusion pump / injector), usability (disposable and reusable), therapeutic area (autoimmune disorders, cardiovascular disorders, metabolic disorders neurological disorders, oncological disorders and other disorders) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
In addition to this, report also provides a detailed market forecast analysis in order to estimate the existing market size and future opportunity for wearable injectors delivering insulin drugs over the coming years. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of device (patch pump / injector and infusion pump / injector), usability (disposable and reusable) and key geographical regions (North America, Europe, Asia, Latin America, and Middle East and North Africa).
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this industry. The market report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.